84 related articles for article (PubMed ID: 2382990)
1. Exogenous interleukin 2 (IL 2) reconstitutes deficient in vitro T-cell growth of patients with chronic lymphocytic leukemia of B-cell lineage (B-CLL).
Jehn U; Gross HJ; Wachholz K; Pauls R
Anticancer Res; 1990; 10(4):929-34. PubMed ID: 2382990
[TBL] [Abstract][Full Text] [Related]
2. Diminished DNA synthesis in T cells from B chronic lymphocytic leukemia after phytohemagglutinin, anti-CD3, and phorbol myristate acetate mitogenic signals.
Prieto A; Garcia-Suarez J; Reyes E; Lapeña P; Hernandez M; Alvarez-Mon M
Exp Hematol; 1993 Nov; 21(12):1563-9. PubMed ID: 8405237
[TBL] [Abstract][Full Text] [Related]
3. In vitro maturation of B cells in chronic lymphocytic leukemia. I. Synergistic action of phorbol ester and interleukin 2 in the induction of Tac antigen expression and interleukin 2 responsiveness in leukemic B cells.
Kabelitz D; Pfeffer K; von Steldern D; Bartmann P; Brudler O; Nerl C; Wagner H
J Immunol; 1985 Oct; 135(4):2876-81. PubMed ID: 2993419
[TBL] [Abstract][Full Text] [Related]
4. Immunobiology of chronic lymphocytic leukemia.
Freedman AS
Hematol Oncol Clin North Am; 1990 Apr; 4(2):405-29. PubMed ID: 2182599
[TBL] [Abstract][Full Text] [Related]
5. Activated autologous T cells exert an anti-B-cell chronic lymphatic leukemia effect in vitro and in vivo.
Di Ianni M; Moretti L; Terenzi A; Bazzucchi F; Del Papa B; Bazzucchi M; Ciurnelli R; Lucchesi A; Sportoletti P; Rosati E; Marconi PF; Falzetti F; Tabilio A
Cytotherapy; 2009; 11(1):86-96. PubMed ID: 19153855
[TBL] [Abstract][Full Text] [Related]
6. Oligonucleotide IMT504 induces an immunogenic phenotype and apoptosis in chronic lymphocytic leukemia cells.
Rodriguez JM; Elias F; Montaner A; Flo J; Lopez RA; Zorzopulos J; Franco RJ; Lenial SP; Lopez Salón M; Pirpignani ML; Solimano J; Garay G; Riveros D; Fernandez J; Cacchione R; Dupont J
Medicina (B Aires); 2006; 66(1):9-16. PubMed ID: 16555722
[TBL] [Abstract][Full Text] [Related]
7. Production of intracellular IL-2, TNF-alpha, and IFN-gamma by T cells in B-CLL.
Gallego A; Vargas JA; Castejón R; Citores MJ; Romero Y; Millán I; Durántez A
Cytometry B Clin Cytom; 2003 Nov; 56(1):23-9. PubMed ID: 14582134
[TBL] [Abstract][Full Text] [Related]
8. Normal T cell colony numbers in untreated patients with chronic lymphocytic leukaemia (CLL).
Fernandez LA; MacSween JM; Langley GR
Br J Haematol; 1984 May; 57(1):97-104. PubMed ID: 6609714
[TBL] [Abstract][Full Text] [Related]
9. Direct cellular interaction with activated CD4(+) T cells overcomes hyporesponsiveness of B-cell chronic lymphocytic leukemia in vitro.
Tretter T; Schuler M; Schneller F; Brass U; Esswein M; Aman MJ; Huber C; Peschel C
Cell Immunol; 1998 Oct; 189(1):41-50. PubMed ID: 9758693
[TBL] [Abstract][Full Text] [Related]
10. Effect of IL-2R beta-binding cytokines on costimulatory properties of chronic lymphocytic leukaemia cells: implications for immunotherapy.
Spaner DE; Hammond C; Mena J; Shi Y
Br J Haematol; 2004 Dec; 127(5):531-42. PubMed ID: 15566356
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-2 prevents programmed cell death in chronic lymphocytic leukemia cells.
Huang RW; Tsuda H; Takatsuki K
Int J Hematol; 1993 Aug; 58(1-2):83-92. PubMed ID: 8219114
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-1 beta, interleukin-1 receptor antagonist and interleukin-6 plasma levels and cytokine gene polymorphisms in chronic lymphocytic leukemia: correlation with prognostic parameters.
Hulkkonen J; Vilpo J; Vilpo L; Koski T; Hurme M
Haematologica; 2000 Jun; 85(6):600-6. PubMed ID: 10870116
[TBL] [Abstract][Full Text] [Related]
13. Vdelta1 T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic B cells and up-regulated by trans-retinoic acid.
Poggi A; Venturino C; Catellani S; Clavio M; Miglino M; Gobbi M; Steinle A; Ghia P; Stella S; Caligaris-Cappio F; Zocchi MR
Cancer Res; 2004 Dec; 64(24):9172-9. PubMed ID: 15604289
[TBL] [Abstract][Full Text] [Related]
14. Expression of interleukin-1 alpha, interleukin-1 beta and interleukin-6 in chronic B lymphocytic leukaemia (B-CLL) cells from patients at different stages of disease progression.
Aguilar-Santelises M; Magnusson R; Svenson SB; Loftenius A; Andersson B; Mellstedt H; Jondal M
Clin Exp Immunol; 1991 Jun; 84(3):422-8. PubMed ID: 2044220
[TBL] [Abstract][Full Text] [Related]
15. Cytoplasmic and surface membrane phenotypic markers in cells of B cell chronic lymphocytic leukemia.
Koníková E; Babusíková O; Mesárosová A; Kusenda J; Glasová M
Neoplasma; 1994; 41(2):69-74. PubMed ID: 8208317
[TBL] [Abstract][Full Text] [Related]
16. Autologous T cells control B-chronic lymphocytic leukemia tumor progression in human-->mouse radiation chimera.
Shimoni A; Marcus H; Dekel B; Shkarchi R; Arditti F; Shvidel L; Shtalrid M; Bucher W; Canaan A; Ergas D; Berrebi A; Reisner Y
Cancer Res; 1999 Dec; 59(23):5968-74. PubMed ID: 10606243
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-2 receptor (Tac antigen) expressed on adult T cell leukemia cells.
Uchiyama T; Hori T; Tsudo M; Wano Y; Umadome H; Tamori S; Yodoi J; Maeda M; Sawami H; Uchino H
J Clin Invest; 1985 Aug; 76(2):446-53. PubMed ID: 2993359
[TBL] [Abstract][Full Text] [Related]
18. Role of decreased production of interleukin-10 and interferon-gamma in spontaneous apoptosis of B-chronic lymphocytic leukemia lymphocytes in vitro.
Djurdjevic P; Zelen I; Ristic P; Baskic D; Popovic S; Arsenijevic N
Arch Med Res; 2009 Jul; 40(5):357-63. PubMed ID: 19766898
[TBL] [Abstract][Full Text] [Related]
19. Antigen modulation followed by quantitative flow cytometry of B-chronic lymphocytic leukemia cells after treatment.
Kusenda J; Babusíková O
Neoplasma; 2004; 51(2):97-102. PubMed ID: 15190418
[TBL] [Abstract][Full Text] [Related]
20. [The heterogeneity of the immunological phenotype and of the proliferative characteristics of the lymphoid cells in chronic B-cell lympholeukemia].
Kariagin IE; Tsveĭbakh AS; Afanas'ev BV
Vopr Onkol; 1992; 38(6):667-74. PubMed ID: 1300767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
